Rivipansel

Description: Rivipansel is a glycomimetic compound. It acts as a pan-selectin antagonist and reverses acute vascular occlusions in sickle cell mice. Target: Others. Smiles: N(C(COCCOCC(NCCNC(=O)[C@H]1C[C@@H](O[C@H]2[C@H](OC(=O)C3=CC=CC=C3)[C@@H](O[C@@H](CC4CCCCC4)C(O)=O)[C@@H](O)[C@@H](CO)O2)[C@H](O[C@H]5[C@@H](O)[C@H](O)[C@H](O)[C@H](C)O5)[C@@H](NC(=O)C6=CC(=O)NC(=O)N6)C1)=O)=O)C=7C8=C(C=C(S(=O)(=O)O)C=C8S(=O)(=O)O)C=C(S(=O)(=O)O)C7. References: Telen MJ, Wun T, McCavit TL, De Castro LM, Krishnamurti L, Lanzkron S, Hsu LL, Smith WR, Rhee S, Magnani JL, Thackray H. Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use. Blood. 2015 Apr 23,125(17):2656-64. doi: 10.1182/blood-2014-06-583351. Epub 2015 Mar 2. PubMed PMID: 25733584, PubMed Central PMCID: PMC4408290.